Bone Marrow Transplantation (BMT) is a popular treatment modality which has proved to be successful in treating hematological malignancies involving the bone marrow (Appelbaum and Fisher 1988; Kim et al. 1990 ). Although survival is improved by BMT, several complications have limited the success of this treatment modality. The most important complications are graft-versus-host disease (O'Reilly 1983; Sullivan 1983 ) and interstitial pneumonitis (IP) (Bortin et al.1982; Meyers et al. 1982) . In the literature, it is reported that IP is associated with severe morbidity and is fatal in half of the cases, whilst no effective treatment is known. Two-thirds of cases are associated with pathogens, most often cytomegalovirus (CMV) (Buckner et al. 1984; Cardozo and Hagenbeek 1985) . However graft-versus-host disease and chemotherapy may also contribute to risk of infection, radiation is considered under the etiology of interstitial pneumonitis (Keane et al. 1981; Shiobara et al. 1982; Robbins et al. 1989; Hartsell et al. 1995; Movsas et al. 1997) .
It is assumed that any portion of the lung that receives a dose of 25 Gy or more with standard fractionation will develop some degree of interstitial pneumonitis and subsequent scarring in 3 to 6 weeks. IP presents with a clinical picture of cough, dyspnea, hypoxemia and diffuse non-lobar infiltrates seen on radiologic imaging. Premorbid lung disease, smoking history, concurrent infections, prior localized chest irradiation and chemotherapeutic agents and/or total body irradiation (TBI) using in BMT conditioning regimen are reported as predisposal factors (Wingard et al. 1988) .
In humans, the lung is one of the most important tissue heterogeneities in the radiation transport due to its gravimetric density. Lung gravimetric density is often set at 0.3 g/cm 3 while other tissues have a density of approximately 1 g/cm 3 and wide lung density variations occur because of the respiratory cycle, age, regional ventilation and perfusion differences, and other pulmonary pathologies. As lung density decreases, total dose to the lung increases and in order to avoid positioning-induced erroneous lung density, estimated density measurements must always be made using positions simulating the actual treatment positions with patient breathing normally.
The chemotherapy using, such as cyclophosphamide, busulfan and other alkylating agents, in BMT conditioning have toxic effect on pulmonary tissue and have synergistic effects with TBI (Peckham and Collins 1981) . Variation in total TBI dose, dose-rates, the use of lung shielding and fractionation may influence the incidence and severity of lung toxicity in any population (Movsas et al. 1997) .
Taking into account the relation of the incidence of radiation pneumonitis to the lung dose, a careful control of the dose administered to the lung is required. Many parameters such as the thickness, size, density, position in the body and the beam quality influence the dose to lung tissue. Pulmonary complications are one of the major causes of mortality following total body irradiation, and one of the factors that unquestionably favor the development of pneumopathies is the dose rate (Bortin et al. 1982; Barrett et al. 1983) .
In the present retrospective study, we examined the effect of total lung dose and dose-rate on IP in fractionated total body irradiation (TBI) for BMT conditioning.
MATERIALS AND METHODS
Between 1987 and 2001, 105 patients received 12 Gy hyperfractionated TBI in 6 fractions, 2 Gy/fr in 3 days with 6 hour gap between 2 fractions each day with Co-60 1.25 MeV teletherapy machine at SAD=370-413.5 cm and diagonal field sizes 174.5-195 cm. The choice of TBI technique significantly affects the success of BMT and particularly the rate of complications. The target volume of TBI is the entire body, fitting the whole body into the limited-size radiation field. The inevitable need to provide homogeneous dose distributions to all sites despite the irregularity in body contour and tissue heterogeneity and limiting the dose to several critical organs imposes major difficulties in treatment planning and radia-tion delivery.
In our fractionated TBI program, the daily positioning of the patients is reproducible providing consistency of dose distribution within each fraction. In our technique shown in Fig. 1 , the thin body sites such as head, neck and legs were in the region of decreasing exposure intensity. Despite individualized phantom calculations and measurements of the neck sites, using of bolus was necessary for homogenization. In the TBI program, the patients lie supine with legs bent on a mobile couch, which has motorized vertical movement. The head and neck are supported, and partially immobilized by a comfortable moulded head-base placed between the rigidly mounted compensators. Partial lung shielding is established by the patient's arms. The position of the patient in the beam is shown in Fig. 1 . The length of the body is fitted to the 1.62 m (85% isodose).
The group was divided into two subgroups of high and low dose-rate TBIs with 28 and 77 patients respectively. The characteristics of these patients are summarized in Table 1 . The median age was 23 years, ranging between 3 and 53 years. Seventy-five of them were males (71.4%) and 30 females (28.6%). The median follow-up time was 12 months ranging between 3 and 177 months. Autologous and allogeneic BMT were achieved in 20 patients (19.04%) and 85 patients (80.95%) respectively. Twelve patients (11.42%) treated for acute myeloid leukemia, 34 patients (32.38%) for acute myeloid leukemia (AML), 22 patients (20.95%) for chronic myeloid leukemia (CML), 25 patients (23.80%) for acute non hodgkin lymphoma (NHL), 5 patients (4.76%) for multiple myeloma (MM), 6 patients (5.71%) for myelodysplastic syndrome (MDS) and 1 patient (0.95%) for myelofibrosis where only 20 patients with NHL (19.04%) received autologous BMT and the rest allogeneic BMT. All patients were conditioned with cyclophosphamide 60 mg/kg/ day for two days + TBI. In GVHD prophylaxis, short-term methotraxate and cyclophosphamide for six months were used.
Four out of 11 patients with lymphoblastic lymphoma received prior mediastinal irradiation with a total dose of 40 Gy. Conditioning radiotherapy was delivered as fractionated 12 Gy TBI in 6 fractions over 3 consecutive days to the midplane at the umbilicus with 6-hour fraction gaps and 2 fractions each day with Co-60 teletherapy machine. In the TBI program, the patients lie supine with legs bent on a mobile couch, which has motorized vertical movement. The head and neck are supported and partially immobilized by a comfortable moulded head-base placed between the rigidly mounted components. Lung shielding is established by the patient's arms. The position of the patient in the beam is shown in Fig. 1 . When dealing with low-density inhomogeneities such as lung, we have used a correction factor (F c ) in lung dose estimation for patient-supinepositioned Co-60 irradiation to figure out the dose increase in the inhomogeneity as compared with homogeneous tissues. This correction factor is a function of the tissue electron density and the dimensions of the inhomogeneity (Geise and McCullough 1977; Sontag et al. 1977) . F c had been calculated by the computerized tomography (CT) numbers measured in Hounsfield Unit of the lungs of 20 supine-positioned patients taken as standard reference for all routine patient calculations in our institution according to the formula: ρ e =(CT number+1000)/1000. We found that lung densities with the patient supine were identical in the right and left lungs (right lung ρ e =0.282±0.048, left lung ρ e =0.292±0.050; n=20, F c =1.16). Pre-TBI lung dose verification has been done using an anthropomorphic phantom and thermoluminescent dosimeters (TLD 100 ) with tissue equivalent compensators placed to simulate arm shielding in the actual patient positioning.
TLD 100 , the lithium fluoride chips with effective atomic number 8.2 compared with 7.4 for soft tissue absorbs the radiation as soft tissue and has the main advantage in measuring doses where ion chamber can not be used as in lung dose measurements (Khan 2003) . Twenty-four out of 105 patients (22.86%) had high dose-rate (>0.04 Gy/min) TBI and 81 out of 105 patients (77.14%) had low dose-rate ( 0.04 Gy/min) TBI.
In the definition of infectious interstitial pneumonia, where radiation-induced pneumonia is also evaluated in the same category histological and microbiologic evaluations of bronchoalveolar lavage (BAL) or lung biopsies were provided by the primary physicians or by the virology or microbiology laboratories. Patients were designated as having idiopathic pneumonia if there were diffuse radiographic multibar infiltrates and no viral or pathogen identified by histology or tissue culture (Roth 1986; Clark et al. 1993) .
This study was performed in compliance with the relevant laws and institutional guidelines. Informed consent was obtained from all human subjects included in the study. Covariates in the patient cohorts with or without pneumonitis were compared with Fischer's exact test or the chi-square test (Fleiss 1973 ) using the SPSS for 
RESULTS
Following BMT with TBI, from 3 to 177 months, in 10 (9.52%) of 105 patients, interstitial pneumonitis developed. Patients had diagnosis of AML in 4, ALL in 2, CML in 2, MM in 1 and NHL in 1. NHL patient who underwent autologous BMT had prior mediastinal irradiation, but other 9 IP patients with allogeneic BMT had no prior chest irradiation. 9 out of 10 IP patients had CMV positivity and no etiology could be identified for one case. The characteristics of IP patients are shown in Table 2 where the total lung doses were estimated doses using lung dose correction factor (F c =1.16).
The median total lung dose was 9.60 Gy, ranging between 8.88 and 10.90 Gy (Table 3) . Age, gender, disease characteristics and GVHD did not differ in LOW and HIGH groups. The total lung dose and IP incidence relation was shown in Fig. 2 . IP occurred in 3.23% (1/31) of patients who received a total lung dose range of 8.88 to 9.26 Gy while the incidence was 18.75% (3/16) for patients who received a total lung dose range of 10.50 to 10.90 Gy and the difference was not statistically significant (p=0.535).
Six patients out of 28 in the HIGH developed IP (21.43%) and 4 patients out of 77 in the LOW developed IP (5.19%). TBI dose-rate vs. IP (%) incidence was shown in Fig. 3 . The difference between dose-rate and IP incidence was statistically significant (p=0.041). 6 out of 10 cases had high-dose rate TBI and 4 had low-dose rate TBI with statistically significant effect on IP.
GVHD is observed only in allogeneic BMT and neither HIGH nor LOW groups had statistically difference on acute or chronic GVHD. Six out of 22 allogeneic BMT patients (27%) with high-dose rate TBI and 15 out of 63 allogeneic BMT patients (23%) with low-dose rate TBI had acute GVHD Grade II-IV whilst 11 out of 22 allogeneic BMT patients (50%) with high-dose rate TBI and 30 out of 63 allogeneic BMT patients (48%) with low-dose rate TBI had chronic GVHD. Four patients with mediastinal irradiation history before TBI have not developed spinal cord and cardiac late effects. In 6 out of 10 patients, IP was fulminant and outcome fatal (60%).
DISCUSSION
In the pulmonary damage following TBIbased BMT, total body irradiation conditioning regimen is speculated to initiate lung toxicity. In the present study, we report a 9.52% incidence rate of IP with TBI-based conditioning regimen in allogeneic and autologous BMT. We have preferred fractionated total body irradiation due to its proved normal tissue sparing effect in conditioning programs (Evans 1983 ), and we have analyzed the effect of total lung dose and dose-rate on IP development. We have delivered 12 Gy TBI and the total lung dose was within the range of 8.88 to 10.90 Gy in 105 patients with a median total lung dose of 9.60 Gy. We have found no doseresponse relationship between total lung doses of 8.88 to 10.90 Gy and the IP incidence, consistent with Sloane et al. (1983) , but contrasting those of Keane et al. (1981) . We consider lung shielding with patients' arms sufficiently effective in avoiding overdosage to the lungs despite differing arm thicknesses.
Different institutions and centers have developed their own technique for decreasing the lung dose Figs. 4a and 4b. During Total Body Irradiation for BMT conditioning, two problems arise in the lungs exposed to total body irradiation. Their density is smaller than that of Total dose of irradiation to lungs (Gy) the remaining tissue, and it's often targeted that they should get a smaller dose to avoid interstitial pneumonia. Relative to lung shielding, the inquiry about TBI (Roth 1982) yield that 22% of the centers don't use any lung shielding, 14% use the arms of the patient, 57% use blocks or compensators and 7% gave no answer. It's called that the upper arm attenuates about 15 to 25%, when the patient is irradiated lateral with 8 MV X-Rays (Chen et al. 2003) . The influence of the lungs is estimated from anthropomorphic phantom measurements from different computational methods, such as TAR-method, Batho-Young Law, and others (Glasgow 1982) , however the size and the density of the lungs are often standardized for all patients (Marinello 1982) . Other centers use constant correction factors between 1.10 and 1.24 whereas we use 1.16 calculation method of which is defined in the methods section. Lung shielding (84%) is used for dose homogenization and for dose reduction. This is realized in 30% by the patient's arms (Fig. 5a ) as in our method and in 60% by standardized or individualized shieldings (Fig. 5b) . Remotely positioned dose modifiers (Figs. 4a and 4b) have the disadvantage of difficult and unreliable alignment. Therefore, some groups prefer to position the dose modifiers in direct contact to the body, e.g. thin lead rubber slabs for lung shielding.
In this analysis, we found significant correlation between increased risk of IP and high dose-rate irradiation consistent with Weiner and colleagues' results (1986) .
The mechanism of how dose-rate of ir- radiation affects the IP incidence in the lung is unknown. Winston et al. (1982) have reported abnormal alveolar macrophage function for several months after BMT in patients receiving TBI at dose-rates 0.06 Gy/min. Although etiology of IP is multifactorial, in order to achieve a successful BMT with improved survival and quality of life, low dose-rate fractionated TBI may be the reliable conditioning regimen resulting in less pulmonary morbidity.
